Therefore, we assessed the efficacy and treatment safety of the IL-23-targeted drugs guselkumab, tildrakizumab, and rizazumab in moderate-to-severe psoriasis using a meta-analysis of all double-blind randomized, placebo-controlled trials. Here, IL23A is linked to psoriasis.